Trial Profile

A phase II trial of CC-122 in patients with non-Hodgkin's lymphoma

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Feb 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avadomide (Primary)
Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
Focus Registrational; Therapeutic Use
Sponsors Celgene Corporation

Most Recent Events

25 Jan 2018 According to Celgene Corporation media release, this trial is expected to initiate in 2018.
27 Jul 2017 According to Celgene Corporation media release, this trial is expected to initiate in second half of 2017.
14 Jan 2016 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com